SCHEMBL23926489

SCHEMBL23926489

Nc1ccc2c(c1)sc(=O)n2C(F)F

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDYL2 Q8N8U2 2/20 0.43
CDYL Q9Y232 2/20 0.43
CNR2 P34972 1/20 0.38
CBX7 O95931 1/20 0.38
CDY1; CDY1B Q9Y6F8 1/20 0.38
BRPF1 P55201 2/20 0.33
SIGMAR1 Q99720 1/20 0.33
ALDH1A1 P00352 5/20 0.33
MAPT P10636 3/20 0.33
CA2 P00918 2/20 0.33
KDM4E B2RXH2 2/20 0.33
GFER P55789 2/20 0.33
GAA P10253 1/20 0.33
SMN1; SMN2 Q16637 5/20 0.33
RAB9A P51151 3/20 0.33
HPGD P15428 3/20 0.33
LMNA P02545 2/20 0.32
NPSR1 Q6W5P4 2/20 0.32
PKM P14618 1/20 0.32
CA1 P00915 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3032933 0.83 CNR2 (0.49) CDYL2CDYLCNR2CBX7CDY1; CDY1B
SCHEMBL23926512 0.78 CDYL2 (0.47) CDYL2CDYLCBX7CDY1; CDY1BALDH1A1
SCHEMBL3035789 0.74 BRPF1 (0.47) CDYL2CDYLCBX7CDY1; CDY1BBRPF1
Hydrochloric Acid SCHEMBL7818310 0.72 BRPF1 (0.46) CDYL2CDYLBRPF1SIGMAR1ALDH1A1
SCHEMBL23926495 0.72 BRPF1 (0.44) BRPF1ALDH1A1MAPTKDM4EGFER
SCHEMBL3045443 0.70 MAPT (0.54) CDYL2CDYLCBX7CDY1; CDY1BSIGMAR1
SCHEMBL22130250 0.70 SLC6A2 (0.31) CNR2SLC6A2SLC6A4
SCHEMBL15712679 0.70 CDYL2 (0.49) CDYL2CDYLCNR2CBX7CDY1; CDY1B
SCHEMBL24130533 0.68 MAPT (0.39) CNR2ALDH1A1MAPTGAASMN1; SMN2
SCHEMBL23926481 0.67 NPC1 (0.37) BRPF1ALDH1A1MAPTCA2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12590071-B2 Hydrazone derivative in which terminal amine group is substituted with aryl group or heteroaryl group, and use thereof KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2026-03-31 US disclosed
CN-113727972-B Novel hydrazone derivatives having terminal amine groups substituted with aryl or heteroaryl groups and use thereof 韩国科学技术研究院 2024-12-27 CN disclosed
CN-115867277-A Novel fused heterocyclyl-carbohydrazone acyldinitrile compounds and use thereof 韩国科学技术研究院 2023-03-28 CN disclosed
US-20220396553-A1 NOVEL HYDRAZONE DERIVATIVE IN WHICH TERMINAL AMINE GROUP IS SUBSTITUTED WITH ARYL GROUP OR HETEROARYL GROUP, AND USE THEREOF KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2022-12-15 US disclosed
CN-113727972-A Novel hydrazone derivatives in which terminal amino group is substituted with aryl or heteroaryl group, and use thereof 韩国科学技术研究院 2021-11-30 CN disclosed
EP-3901139-A1 NOVEL HYDRAZONE DERIVATIVE WITH ARYL OR HETEROARYL GROUP SUBSTITUTED AT TERMINAL AMINE GROUP THEREOF AND USE THEREOF Korea Institute of Science and Technology (KR) 2021-10-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12590071-B2 Hydrazone derivative in which terminal amine group is substituted with aryl group or heteroaryl group, and use thereof ABL1, TH, CYP3A43 CDYL2 1535/4885CDYL 867/4885CNR2 677/4885
US-20220396553-A1 NOVEL HYDRAZONE DERIVATIVE IN WHICH TERMINAL AMINE GROUP IS SUBSTITUTED WITH ARYL GROUP OR HETEROARYL GROUP, AND USE THEREOF AANAT, NAT1, HNMT CDYL2 992/4885CDYL 722/4885CNR2 378/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.